*Michael G. DeGroote School of Medicine, McMaster University, Hamilton, Ontario, Canada;

†Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada;

‡Department of Ophthalmology and Vision Sciences, University of Toronto, Toronto, Ontario, Canada;

§Unity Health, St. Joseph's Health Centre, University of Toronto, Toronto, Ontario, Canada;

¶Department of Ophthalmology, Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada;

**John and Liz Tory Eye Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada; and

††Department of Ophthalmology, St. Michael's Hospital/Unity Health Toronto, Toronto, Ontario, Canada.

Reprint requests: Rajeev H. Muni, MD, MSc, Department of Ophthalmology, St Michael's Hospital/Unity Health Toronto, 30 Bond St, Donnelly Wing, 8th Floor, Toronto, ON M5B 1W8, Canada; e-mail: [email protected]

N. S. Patil: None; A. Mihalache: None; R. Huang: None; J. Kwok: None; E. Kisilevsky: None; M. M. Popovic: Financial support (to institution)—PSI Foundation, Fighting Blindness Canada; P. J. Kertes: Advisory board—Novartis, Alcon, Bayer, Roche, Novelty Nobility; Financial support (to institution)—Bayer, RegenXBio, Roche, Novartis; Financial support—Novartis, Bayer; Equity owner—ArcticDx; R. H. Muni: Advisory board—Alcon, Bausch + Lomb, Bayer, Novartis, Allergan, Roche; Financial Support (to institution)—Bayer, Novartis, Roche; R. P. Kohly: Financial Support (to institution)—Bayer, Novartis. R. H. Muni's research is supported by the Silber TARGET fund.

Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Web site (www.retinajournal.com).